News Mauna Kea Technologies

Equities

ALMKT

FR0010609263

Market Closed - Euronext Paris Other stock markets 11:29:12 2024-05-07 am EDT			5-day change	1st Jan Change
0.406 ^EUR	+2.01%		+1.00%	-13.80%

Apr. 30	Mauna Kea Technologies SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 29	Mauna Kea Technologies SA Announces the Opening of A French Center of Excellence for the Use of Cellvizio in Lung Cancer Diagnostics	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mauna Kea Technologies Announces 9 Presentations Demonstrating the Clinical Value of Cellvizio® at Digestive Disease Week® 2024	May. 06	BU
Mauna Kea Technologies: Publication of the 2023 Annual Financial Report	Apr. 30	BU
Mauna Kea Technologies : Publication of the 2023 Annual Financial Report	Apr. 30	PU
Mauna Kea Technologies SA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29	CI
Mauna Kea Technologies Announces the Opening of a French Center of Excellence for the Use of Cellvizio® in Lung Cancer Diagnostics	Apr. 29	BU
Mauna Kea Technologies SA Announces the Opening of A French Center of Excellence for the Use of Cellvizio in Lung Cancer Diagnostics	Apr. 29	CI
Mauna Kea Technologies : Inside Information / Information on annual revenues	Apr. 25	PU
Mauna Kea Technologies Reports Full Year 2023 Results and Q1 2024 Sales	Apr. 25	BU
Mauna Kea Technologies SA Provides Sales Guidance for the Year 2024	Apr. 25	CI
Mauna Kea Technologies : Reports Full Year 2023 Results and Q1 2024 Sales	Apr. 25	PU
Mauna Kea Technologies Executes Agreement to Restructure its Existing Loan Agreement with the European Investment Bank	Apr. 24	BU
Mauna Kea: first Italian center for Cellvizio	Apr. 03	CF
Mauna Kea Technologies Announces the Opening of the First Italian Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults	Apr. 02	BU
Mauna Kea Technologies : Announces the Opening of the First Italian Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults	Apr. 02	PU
Mauna Kea Technologies Partners with V7 to Develop Innovative AI Applications with Cellvizio	Mar. 27	BU
Mauna Kea Technologies Partners with V7 to Develop Innovative AI Applications with Cellvizio	Mar. 27	CI
Mauna Kea: partnership with Metrodora Institute in the USA	Mar. 06	CF
Mauna Kea Technologies Partners with Metrodora to Create First U.S. Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults	Mar. 06	BU
Mauna Kea Technologies Partners with Metrodora to Create First U.S. Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults	Mar. 06	CI
MAUNA KEA TECHNOLOGIES REPORTS FULL YEAR 2023 SALES OF EUR10.5M, UP +42% VS 2022	Jan. 26	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Mauna Kea Technologies

Equities

ALMKT

FR0010609263

Summary

Filters